Free Trial
NASDAQ:CGTX

Cognition Therapeutics Q3 2023 Earnings Report

Cognition Therapeutics logo
$0.33 -0.03 (-7.81%)
Closing price 05/8/2025 03:58 PM Eastern
Extended Trading
$0.32 -0.01 (-1.53%)
As of 09:14 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Cognition Therapeutics EPS Results

Actual EPS
-$0.22
Consensus EPS
-$0.31
Beat/Miss
Beat by +$0.09
One Year Ago EPS
N/A

Cognition Therapeutics Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Cognition Therapeutics Announcement Details

Quarter
Q3 2023
Time
N/A
Conference Call Date
Thursday, November 2, 2023
Conference Call Time
7:00AM ET

Cognition Therapeutics Earnings Headlines

URGENT: Someone's Moving Gold Out of London...
People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “gold analysts” have it all wrong… They tell you to invest in gold ETFs - because the popular mining ETFs will someday catch fire and close the price gap with spot gold.
See More Cognition Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Cognition Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Cognition Therapeutics and other key companies, straight to your email.

About Cognition Therapeutics

Cognition Therapeutics (NASDAQ:CGTX), a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its lead product candidate is CT1812, an orally delivered molecule modulator designed to penetrate the blood-brain barrier and bind selectively to the S2R complex, which is in Phase 2 clinical trial for the treatment of Alzheimer's disease, as well as geographic atrophy secondary to dry age-related macular degeneration and synucleinopathies, such as dementia with Lewy bodies. The company was incorporated in 2007 and is headquartered in Purchase, New York.

View Cognition Therapeutics Profile

More Earnings Resources from MarketBeat